Oxygen Biotherapeutics Inc is categorized under Biotherapeutics in Costa Mesa, CA and active since 2007.
Oxygen Biotherapeutics Inc was established in 2007, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Biotherapeutics business, which does work in the BOTH market, and is classified as a Biotherapeutics, under code number 424210 by the NAICS.
If you are seeking more information, feel free to contact Robert Nicora at the company’s single location by writing to 3189 Airway Avenue # C, Costa Mesa, California CA 92626 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Oxygen Biotherapeutics Inc |
| Contact Person: | Robert Nicora |
| Address: | 3189 Airway Avenue # C, Costa Mesa, California 92626 |
| Website Address: | oxygenbiotherapeutics.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B & B2C |
| Business Category: | Biotherapeutics |
| SIC Code: | 5122 |
| NAICS Code: | 424210 |
| Share This Business: |
Oxygen Biotherapeutics Inc was started in 2007 to provide professional Biotherapeutics under the SIC code 5122 and NAICS code 424210. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Robert Nicora for inquiries that concern Oxygen Biotherapeutics Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Oxygen Biotherapeutics Inc can be found at the coordinates 33.682072,-117.86959 as well as the street address 3189 Airway Avenue # C in Costa Mesa, California 92626.
For its online presence, you may visit Oxygen Biotherapeutics Inc’s website at oxygenbiotherapeutics.com and engage with its social media outlets through on Twitter and on Facebook.